CoChat

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

Open access
Kawakami, Hisato, Okamoto, Isamu, Yonesaka, Kimio, Okamoto, Kunio, Shibata, Kiyoko, Shinkai, Yume, Sakamoto, Haruka, Kitano, Michiko, Tamura, Takao, Nishio, Kazuto, Nakagawa, Kazuhiko · 2014 · Oncotarget
Cited by 78

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Hisato Kawakami 1 , Isamu Okamoto 1, 2 , Kimio Yonesaka 1 , Kunio Okamoto 1 , Kiyoko Shibata 1 , Yume Shinkai 1 , Haruka Sakamoto 1 , Michiko Kitano 1 , Takao Tamura 1 , Kazuto Nishio 3 , Kazuhiko Nakagawa 1 1 Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-sayama, Osaka 589-8511, Japan 2 Center for Clinical and Translational Research, Kyushu University Hospital, Higashiku, Fukuoka 812–8582, Japan 3 Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, Osaka 589–8511, Japan Correspondence to: Isamu Okamoto, e-mail: okamotoi@kokyu.med.kyushu-u.ac.jp Keywords: colorectal cancer, heregulin, resistance, cetuximab, patritumab Received: September 21, 2014 Accepted: October 26, 2014 Published: December 19, 2014 ABSTRACT We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) cells that are highly sensitive to cetuximab were engineered to stably express heregulin by retroviral infection, and the effects of cetuximab and patritumab on the resulting DiFi-HRG cells were examined. DiFi-HRG cells released substantial amounts of heregulin and showed resistance to cetuximab. Cetuximab alone inhibited EGFR and ERK phosphorylation in DiFi-HRG cells, but it had no effect on the phosphorylation of HER2, HER3, or AKT, suggesting that sustained AKT activation by HER2 and HER3 underlies cetuximab resistance in these cells. In contrast, patritumab in combination with cetuximab markedly inhibited the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. The combination therapy also inhibited the growth of DiFi-HRG tumor xenografts in nude mice to a greater extent than did treatment with either drug alone. Activation of HER2-HER3 signaling associated with the operation of a heregulin autocrine loop confers resistance to cetuximab, and patritumab is able to restore cetuximab sensitivity through inhibition of heregulin-induced HER3 activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2663

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Kawakami, H., Okamoto, I., Yonesaka, K., Okamoto, K., Shibata, K., Shinkai, Y., Sakamoto, H., Kitano, M., Tamura, T., Nishio, K., & Nakagawa, K.
Venue
Oncotarget
Published
2014-12-05
Volume
5
Issue
23
Pages
11847-11856
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1544959878
Cited by
78
References
9
FWCI
5.17
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.